You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search
Tuberculosis (TB)
Articles on Tuberculosis
Guidelines: Treatment of Tuberculosis (6/20/2003)
Guidelines for Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children (9/4/2009)
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (4/10/2009)
CDC Tuberculosis Fact Sheets
General Information
Basic TB information, Difference between latent TB & active TB disease,
Data & Statistics
TB trends, TB Genotyping, RVCT, NTIP...
Drug-Resistant TB
Multidrug-resistant TB (MDR TB), Extensively drug-resistant TB (XDR TB)
Infection Control & Prevention
Respiratory protection, Health-Care Settings, International Travelers...
TB in Specific Populations
TB & HIV, Pregnancy, International travelers
Treatment
Treatments regimens for latent TB infection & TB disease, Drug-resistant TB, TB & HIV...
Testing & Diagnosis
Tuberculin skin testing, QuantiFeron(R)-TB Gold Test, Diagnosis of TB
Vaccines & Immunizations
BCG Vaccine,



Articles on Tuberculosis
Updated CDC HIV and TB Fact Sheet
6-28-2011
Shorter Treatment More Effective for Latent TB
5-24-2011
FDA Approves Rapid Test for MRSA
5-13-2011
Study Finds No XMRV-Chronic Fatigue Link
5-10-2011
TB Fixed-dose Coformulation Works as Well as Separate Drugs
4-15-2011
Immediate ART Improves Survival for HIV+ People with TB
3-18-2011
Tuberculosis Coinfection Increases Risk of Mother-to-Child HIV Transmission
2-01-2011
Tuberculosis Late Diagnosis and Mortality Decrease among HIV Positive People in U.S.
12-14-2010
More than 1 Million People Are Coinfected with HIV and Tuberculosis, WHO Report Says
11-19-2010
Experimental Drug TMC207 Cuts Response Time for Multidrug-resistant Tuberculosis
10-04-2010
New Tuberculosis Test Enables Fast and Accurate Diagnosis and Identification of Drug Resistance
9-10-2010
FDA Drafts New Rules for Testing and Approval of Combination Regimens for Diseases such as Tuberculosis and HIV
3-26-2010
Starting Antiretroviral Therapy during Tuberculosis Treatment Is Safer than Waiting, despite Potential Drug Interactions
3-26-2010
World Health Organization Report Reveals Record Levels of Multidrug-resistant and Extensively Drug-resistant Tuberculosis
3-23-2010
First Case of Extremely Drug-resistant Tuberculosis in the U.S.
1-5-2010
Tuberculosis (TB): An Overview from the U.S. Centers for Disease Control and Prevention
12-04-09
Is It Possible to Eliminate Tuberculosis?
10-23-2009
Current Guidelines Need to Be Changed for Both First-line Treatment and Re-treatment of Tuberculosis, Experts Say
9-18-2009
How Infectious Are Tuberculosis Patients Coinfected with HIV?
8-18-2009
New Drug-resistant Tuberculosis Strains Could Become Widespread
8-18-2009
IAS 2009 Opening Session Emphasizes Need for Expanded Treatment of HIV and Tuberculosis in Developing Countries
7-24-2009
Research Offers Guidance on Scaling Up HIV and Tuberculosis Treatment Programs in Resource-limited Countries
7-24-2009
Widespread Use of Antiretroviral Therapy Associated with a Large Decrease in Tuberculosis Prevalence in South Africa
7-24-2009
World Health Organization (WHO) Says the BCG Tuberculosis Vaccine Is Too Dangerous for HIV Positive Infants
7-14-2009
Laboratory Study Helps Explain Why People with HIV Are More Susceptible to Tuberculosis
7-10-2009
TB Alliance and Tibotec Form Collaboration to Develop New Drugs for Tuberculosis
6-19-2009
Promising Interim Results of a Study of TMC207, a New Experimental Drug for Treatment of Multidrug-resistant Tuberculosis (MDR-TB)
6-5-2009
WHO Releases New Report on Tuberculosis and Its Impact on People with HIV/AIDS
3/31/09
Preventive Isoniazid plus HAART Lowers the Risk of Active Tuberculosis among HIV Patients by 89%
3/31/09
WHO Releases New Report on Tuberculosis and Its Impact on People with HIV/AIDS
3/27/09
Preventive Isoniazid plus HAART Lowers the Risk of Active Tuberculosis among HIV Patients by 89%
3/27/09

Multidrug-Resistant Tuberculosis (MDR TB)
and Possible Effective Treatments

MDR TB occurs when a Mycobacterium tuberculosis strain is resistant to isoniazid and rifampin, two of the most powerful first-line drugs. To cure MDR TB, healthcare providers must turn to a combination of second-line drugs, several of which are shown here.